Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line

Diseases of the Esophagus

Volumn 21, Issue 6, 2008, Pages 514-521

  Keswani, R N ^a   Chumsangsri, A ^a   Mustafi, R ^a   Delgado, J ^a   Cohen, E E W ^a   Bissonnette, Marc ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE   (United States)

Author keywords

Bile acid; Esophageal cancer; Gastroesophageal reflux; p38; RAF inhibitor

Indexed keywords

ACID; BILE ACID; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SORAFENIB; TAUROCHOLIC ACID;

ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STIMULATION; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; BARRETT ESOPHAGUS; BENZENESULFONATES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROBABILITY; PROTEIN KINASE INHIBITORS; PYRIDINES; REFERENCE VALUES;

EID: 51249087297     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00799.x     Document Type: Article

References (55)

1. Devesa S S, Blot W J, Fraumeni J F Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
2. Blot W J, Devesa S S, Kneller R W, Fraumeni J F Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-9.
3. Pohl H, Welch H G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6.
4. Haggitt R C. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
5. Winters C Jr, Spurling T J, Chobanian S J et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
6. Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 106-12.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
8. Jankowski J A, Anderson M. Review article: Management of oesophageal adenocarcinoma -control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther 2004; 20: 71-80; discussion 95-6.
9. Fitzgerald R C, Omary M B, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120-8.
10. Cooper B T, Chapman W, Neumann C S, Gearty J C. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: Observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23: 727-33.
11. El-Serag H B, Aguirre T V, Davis S, Kuebeler M, Bhattacharyya A, Sampliner R E. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.
12. Souza R F, Shewmake K, Terada L S, Spechler S J. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299-307.
13. Souza R F, Shewmake K, Pearson S et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004; 287: G743-8.
14. Jaiswal K, Lopez-Guzman C, Souza R F, Spechler S J, Sarosi G A Jr. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006; 290: G335-42.
15. Sommerer F, Vieth M, Markwarth A et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004; 23: 554-8.
16. Arber N, Shapira I, Ratan J et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 2000; 118: 1045-50.
17. Souza R F, Shewmake K L, Shen Y et al. Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus. Am J Gastroenterol 2005; 100: 551-9.
18. Vaezi M F, Richter J E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192-9.
19. Vaezi M F, Richter J E. Bile reflux in columnar-lined esophagus. Gastroenterol Clin North Am 1997; 26: 565-82.
20. Stein H J, Feussner H, Kauer W, DeMeester T R, Siewert J R. Alkaline gastroesophageal reflux: Assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg 1994; 167: 163-8.
21. Bani-Hani K, Martin I G, Hardie L J et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316-21.
22. Arber N, Lightdale C, Rotterdam H et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996; 5: 457-9.
23. Izzo J G, Wu T T, Wu X et al. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 2007; 25: 698-707.
24. Albanese C, Johnson J, Watanabe G et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270: 23589-97.
25. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-44.
26. Wilhelm S, Chien D S. BAY 43-9006: Preclinical data. Curr Pharm Des 2002; 8: 2255-7.
27. Wilhelm S M, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
28. Rini B I. Sorafenib. Expert Opin Pharmacother 2006; 7: 453-61.
29. Adnane L, Trail P A, Taylor I, Wilhelm S M. Sorafenib (BAY 43-9006, Nexavar (R)), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth Enzymol 2005; 407: 597-612.
30. Ratain M J, Eisen T, Stadler W M et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
31. Richly H, Henning B F, Kupsch P et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006; 17: 866-73.
32. Carlson N, Lechago J, Richter J et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 2002; 97: 1340-5.
33. Bissonnette M, Khare S, von Lintig F C et al. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: Effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Cancer Res 2000; 60: 4602-9.
34. Zhang W, Liu H T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12: 9-18.
35. Gibson M K, Abraham S C, Wu T T et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-8.
36. Cohen G, Mustafi R, Chumsangsri A et al. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006; 66: 5656-64.
37. Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science 2005; 308: 1248-9.
38. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10: 6388S-92S.
39. Panka DJ, Wang W, Atkins M B, Mier J W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006; 66: 1611-19.
40. Morales C P, Souza R F, Spechler S J. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002; 360: 1587-9.
41. Auvinen M I, Sihvo E I, Ruohtula T et al. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002; 20: 2971-9.
42. Kelty C J, Ackroyd R, Brown N J, Stephenson T J, Stoddard C J, Reed M W. Endoscopic ablation of Barrett's oesophagus: A randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-96.
43. Mino-Kenudson M, Brugge W R, Puricelli W P et al. Management of superficial Barrett's epithelium-related neoplasms by endoscopic mucosal resection: Clinicopathologic analysis of 27 cases. Am J Surg Pathol 2005; 29: 680-6.
44. van Lanschot J J, Hulscher J B, Buskens C J, Tilanus H W, ten Kate F J, Obertop H. Hospital Volume and hospital mortality for esophagectomy. Cancer 2001; 91: 1574-8.
45. Keswani RN, Noffsinger A, Waxman I, Bissonnette M. Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2006; 15: 1243-9.
46. Johnston MH. Technology insight: Ablative techniques for Barrett's esophagus - current and emerging trends. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 323-30.
47. Ross A S, Kinney T P, Larghi A, Stearns L, Dye C, Waxman I. Complete circumferential endoscopic mucosal resection as a treatment for early esophageal carcinoma or Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2005; 61: AB95-AB95.
48. Shirvani V N, Ouatu-Lascar R, Kaur B S, Omary M B, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96.
49. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273: 2424-8.
50. Anderson L A, Johnston B T, Watson R G et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006; 66: 4975-82.
51. Vaughan T L, Dong L M, Blount P L et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. Lancet Oncol 2005; 6: 945-52.
52. Kaur B S, Khamnehei N, Iravani M, Namburu S S, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-7.
53. Bresalier R S, Sandler R S, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
54. Spechler S J. Clinical practice. Barrett's Esophagus N Engl J Med 2002; 346: 836-42.
55. Walsh T N, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.